Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

CANF Relative to the S&P 500

CANF Relative to the Sector

% of Revenue Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Can-Fite Biopharma Ltd. (AMEX:CANF) seasonal charts above shows that a Buy Date of September 6 and a Sell Date of December 2 has resulted in a geometric average return of 4.31% above the benchmark rate of the S&P 500 Total Return Index over the past 12 years. This seasonal timeframe has shown positive results compared to the benchmark in 6 of those periods. This is a poor rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 12 years by an average of 51.23% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company’s platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company’s?drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite’s liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the?common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

To download CANF seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: CANF